Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Immutep's IMP761 significantly suppresses T-cell immune responses in Phase I trial

By Public Technologies
  • Immutep reported positive Phase I results for autoimmune drug candidate IMP761, presented in a late-breaking abstract at ACR Convergence 2026.
  • A single infusion significantly suppressed T-cell-driven immune responses in healthy volunteers, with stronger effects at higher exposure.
  • IMP761 was well tolerated across all seven dose levels, with no serious or severe adverse events reported.
  • The drug’s pharmacokinetic profile supports dosing every four weeks; the ongoing multiple-dose study has shown no new safety signals.
  • Multiple-dose results are expected in the first half of 2027 to guide dose selection for a potential Phase II program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611081734PRIMZONEFULLFEED9872954) on November 08, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.